How haplotypes can be phased with Xdrop™ and single molecule sequencing
Standard genotyping arrays, Sanger sequencing and short-read sequencing (e.g. Illumina NGS), commonly used in cancer research, identify the mutations present without revealing their arrangement as haplotypes. Xdrop™ enrichment followed by single molecule long-read sequencing enables researchers to resolve haplotype phasing in human cancer samples easier and quicker than current methods. This has been demonstrated by researchers at the SciLifeLab, Uppsala University and Cancer Center at Karolinska Institute in collaboration with Samplix.
Briefly explained, five different primer sets were designed with the Samplix online design tool to amplify different ~200 bp regions distributed across a 70 Kb region on chromosome 17p13 encompassing the entire TP53 gene.
After the Xdrop™ dPCR enrichment and dMDA amplification steps, the harvested DNA was subjected to SMRTbell library preparation followed by PacBio long read sequencing. Due to the enrichment, the region was deeply sequenced, and high accuracy consensus reads where aligned. The high fidelity of consensus sequence allowed the haplotype phasing of three mutations located several hundred nucleotides apart (see figure A below). Phasing of three pathogenic mutations; c.913A>T (nonsense), c.673-2A>T (splice site), c.701A>G (missense) and normal wildtype (WT) revealed that none of the point mutations occurred in the same consensus read, meaning the mutations were present on separate alleles in the CLL patient cell population.
Figure A. Phasing of three pathogenic mutations;
913A>T (nonsense), 673-2A>T (splice site), 701A>G (missense) and normal wildtype (WT) in a single CLL patient sample.
Each of the grey lines shows a consensus read. A mutation is indicated with a colored line across this. Red boxes indicate locations of the three mutations. As seen in the data and schematically drawn, none of the point mutations occur in the same consensus read, meaning they are present on separate alleles in the CLL patient cell population.
ContactMileparken 282730 HerlevDenmark
email@example.comPhone: (+45) 82 30 45 00
CVR 32 30 93 21
Connect with us
2019 Samplix ApS. All rights reserved. For Research Use Only. Not for use in diagnostic procedures.